New pill shows 60 per cent LDL reduction in trials: Cardiologists break down if it reduces heart attack risk
A new oral PCSK9 inhibitor, enlicitide, offers a daily pill option for lowering LDL-C, a key cardiovascular disease risk factor. A clinical trial showed a significant 58.2% LDL-C reduction in patients already on statins, with mild side effects. This oral formulation simplifies cholesterol management, potentially improving adherence and access to treatment.
A new oral PCSK9 inhibitor, enlicitide, offers a daily pill option for lowering LDL-C, a key cardiovascular disease risk factor. A clinical trial showed a significant 58.2% LDL-C reduction in patients already on statins, with mild side effects. This oral formulation simplifies cholesterol management, potentially improving adherence and access to treatment.
